SRC and breast cancer: Moreover, c-Src also phosphorylates LDHA at Y10, increasing its activity, which correlates with metastasis progression of clinical tumor samples of breast cancer [19], while as shown here, the dominant-negative variant of c-Src, the SrcDN counteracted these effects.